DK1311279T3 - Behandling af hepatitis C med thymosin, interferon og ribavirin - Google Patents

Behandling af hepatitis C med thymosin, interferon og ribavirin

Info

Publication number
DK1311279T3
DK1311279T3 DK01962344T DK01962344T DK1311279T3 DK 1311279 T3 DK1311279 T3 DK 1311279T3 DK 01962344 T DK01962344 T DK 01962344T DK 01962344 T DK01962344 T DK 01962344T DK 1311279 T3 DK1311279 T3 DK 1311279T3
Authority
DK
Denmark
Prior art keywords
hepatitis
thymosin
interferon
ribavirin
treatment
Prior art date
Application number
DK01962344T
Other languages
Danish (da)
English (en)
Inventor
Alfred R Rudolph
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Application granted granted Critical
Publication of DK1311279T3 publication Critical patent/DK1311279T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK01962344T 2000-08-07 2001-08-06 Behandling af hepatitis C med thymosin, interferon og ribavirin DK1311279T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22331700P 2000-08-07 2000-08-07
PCT/US2001/041550 WO2002011749A1 (en) 2000-08-07 2001-08-06 Treatment of hepatitis c with thymosin, interferon and ribavirin

Publications (1)

Publication Number Publication Date
DK1311279T3 true DK1311279T3 (da) 2007-02-12

Family

ID=22835988

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01962344T DK1311279T3 (da) 2000-08-07 2001-08-06 Behandling af hepatitis C med thymosin, interferon og ribavirin

Country Status (18)

Country Link
EP (1) EP1311279B1 (de)
KR (1) KR100851861B1 (de)
CN (1) CN1446096A (de)
AT (1) ATE348628T1 (de)
AU (2) AU2001283536B2 (de)
BR (1) BR0113115A (de)
CA (1) CA2418085A1 (de)
CY (1) CY1106388T1 (de)
DE (1) DE60125377T2 (de)
DK (1) DK1311279T3 (de)
EA (1) EA007785B1 (de)
ES (1) ES2275711T3 (de)
HK (1) HK1055689A1 (de)
IL (1) IL154299A0 (de)
MX (1) MXPA03001145A (de)
NZ (1) NZ524579A (de)
PT (1) PT1311279E (de)
WO (1) WO2002011749A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102171186A (zh) * 2008-08-06 2011-08-31 赛生制药有限公司 采用免疫调节剂化合物治疗或预防丙型肝炎
JP2012526149A (ja) 2009-05-08 2012-10-25 サイクローン・ファーマシューティカルズ・インコーポレイテッド ワクチン増強剤としてのαチモシンペプチド
RU2473341C1 (ru) * 2011-08-02 2013-01-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Сибирский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации (ГБОУ ВПО СибГМУ Минздравсоцразвития) Способ профилактики вертикальной передачи вирусов гепатитов в и с у беременных с реактивацией вирусов в третьем триместре

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW224053B (de) * 1991-09-13 1994-05-21 Paul B Chretien
US5610054A (en) * 1992-05-14 1997-03-11 Ribozyme Pharmaceuticals, Inc. Enzymatic RNA molecule targeted against Hepatitis C virus
US5849800A (en) * 1997-03-28 1998-12-15 The Penn State Research Foundation Use of amantadine for treatment of Hepatitis C
ATE307597T1 (de) * 1998-06-08 2005-11-15 Hoffmann La Roche Verwendung von peg-ifn-alpha und ribavirin zur behandlung chronischer hepatitis c
AU2157000A (en) * 1998-12-18 2000-07-12 Schering Corporation Ribavirin-pegylated interferon alfa induction hcv combination therapy

Also Published As

Publication number Publication date
EA007785B1 (ru) 2007-02-27
AU8353601A (en) 2002-02-18
EA200300222A1 (ru) 2003-08-28
EP1311279A1 (de) 2003-05-21
DE60125377D1 (de) 2007-02-01
CA2418085A1 (en) 2002-02-14
AU2001283536B2 (en) 2005-09-01
ATE348628T1 (de) 2007-01-15
CN1446096A (zh) 2003-10-01
EP1311279B1 (de) 2006-12-20
PT1311279E (pt) 2007-03-30
NZ524579A (en) 2004-06-25
MXPA03001145A (es) 2004-08-02
KR20030034129A (ko) 2003-05-01
DE60125377T2 (de) 2007-09-27
KR100851861B1 (ko) 2008-08-13
HK1055689A1 (en) 2004-01-21
EP1311279A4 (de) 2004-08-11
WO2002011749A1 (en) 2002-02-14
BR0113115A (pt) 2003-06-10
CY1106388T1 (el) 2011-10-12
ES2275711T3 (es) 2007-06-16
IL154299A0 (en) 2003-09-17

Similar Documents

Publication Publication Date Title
AR021876A1 (es) Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
DK1658302T3 (da) Purinnukleosidanaloge til behandling af sygdomme forårsaget af Flavirividae, herunder hepatitis C
AR023541A1 (es) Terapia de combinacion para vhc
NO20025627D0 (no) Fremgangsmåter og sammensetninger for å behandle hepatitt C virus
PT956861E (pt) Terapia combinada compreendendo ribavirina e interferao alfa em doentes sem tratamento antiviral anterior tendo infeccao cronica pelo virus da hepatite c
PL1778272T3 (pl) Zastosowanie kombinacji cyklosporyny i pegylowanych interferonów do leczenia zapalenia wątroby typu C (HCV)
HK1084862A1 (en) Use of omega interferon in the manufacturing of a medicament for treating viral disease in a warm-blooded animal subject
AR022116A1 (es) Terapia de combinacion para el vhc por induccion de ribavirina - interferon alfa
DK1115420T3 (da) Behandling af hepatitis B med thymosin-alpha-1 og lamivudin
DK1311279T3 (da) Behandling af hepatitis C med thymosin, interferon og ribavirin
DK1311286T3 (da) Behandling af hepatitis C med thymosin og pegyleret interferon
AR036698A1 (es) Metodo para el tratamiento de la infeccion por virus de hepatitis c en pacientes sin respuesta a tratamiento
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
ECSP993003A (es) Uso de peg - ifn -alpha y ribavirina para el tratamiento de hepatitis c cronica
RU99125410A (ru) Способ лечения хронических вирусных гепатитов
ECSP003446A (es) Terapia de combinacion para vhc